Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Biogen gptkb:Genentech gptkb:Denali_Therapeutics |
| gptkbp:example |
gptkb:DNL151
gptkb:DNL201 gptkb:MLi-2 gptkb:PF-06447475 GNE-7915 |
| gptkbp:investigationalStatus |
clinical trials
|
| gptkbp:mechanismOfAction |
inhibition of LRRK2 kinase activity
|
| gptkbp:relatedTo |
gptkb:autosomal_dominant_Parkinson's_disease
|
| gptkbp:researchInterest |
neuroprotection
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
kidney toxicity
lung toxicity |
| gptkbp:target |
LRRK2 protein
|
| gptkbp:targetedMutation |
G2019S mutation in LRRK2
|
| gptkbp:usedFor |
gptkb:Parkinson's_disease
|
| gptkbp:bfsParent |
gptkb:LRRK2_gene
|
| gptkbp:bfsLayer |
8
|
| http://www.w3.org/2000/01/rdf-schema#label |
LRRK2 kinase inhibitors
|